Bayer Logo Bayer Logo Bayer Logo Bayer Logo

About Us


Recent years have witnessed substantial improvements in the organisation of comprehensive care for people born with haemophilia. Since the introduction of clotting factor concentrates in the 1960s and prophylaxis in the 1970s, the life expectancy of people with haemophilia in developed countries has increased from less than 30 years to over 70 years.1,2 As a consequence, the ageing haemophilia population now faces the same age-related co-morbidities as the general population.3-5


Little is known about how to manage cardiovascular disease, cancer, dementia, and other age-related diseases in the older haemophilia population. Recognising the importance of how age-related diseases might affect people with haemophilia, Bayer HealthCare supported the launch of the ADVANCE Working Group in 2009.


The ADVANCE Working Group is a panel of experienced haemophilia treaters from across Europe who wish to raise awareness of such issues and to consider how management and treatment should best be adapted for people with haemophilia. Under the chairmanship of Gerry Dolan (UK) and Philippe de Moerloose (CH), ADVANCE has developed recommendations and ongoing studies which aim to:


  •  Highlight key issues associated with the ageing haemophilia population
  •  Identify how management of age-related co-morbidities should be adapted to those with haemophilia
  •  Encourage the development of further research focusing on the ageing haemophilia population
  •  Generate recommendations that can be used by clinicians across Europe
    1. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with philia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-825.
    2. Plug I, Van Der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, et al. Mortality and causes of death in patients with philia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-516.
    3. Street A, Hill K, Sussex B, Warner M, Scully MF. Haemophilia and ageing. Haemophilia 2006; 12 Suppl 3: 8-12.
    4. Mauser-Bunschoten EP, Fransen Van De Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-863.
    5. Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009; 15: 1197-1209.